JP2017537899A5 - - Google Patents

Download PDF

Info

Publication number
JP2017537899A5
JP2017537899A5 JP2017526088A JP2017526088A JP2017537899A5 JP 2017537899 A5 JP2017537899 A5 JP 2017537899A5 JP 2017526088 A JP2017526088 A JP 2017526088A JP 2017526088 A JP2017526088 A JP 2017526088A JP 2017537899 A5 JP2017537899 A5 JP 2017537899A5
Authority
JP
Japan
Prior art keywords
compound
therapeutic agent
dissolution
formula
elution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017526088A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017537899A (ja
JP6829684B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/061194 external-priority patent/WO2016081523A1/en
Publication of JP2017537899A publication Critical patent/JP2017537899A/ja
Publication of JP2017537899A5 publication Critical patent/JP2017537899A5/ja
Application granted granted Critical
Publication of JP6829684B2 publication Critical patent/JP6829684B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017526088A 2014-11-17 2015-11-17 癌を処置する方法 Active JP6829684B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462080985P 2014-11-17 2014-11-17
US62/080,985 2014-11-17
US201562166572P 2015-05-26 2015-05-26
US62/166,572 2015-05-26
US201562251903P 2015-11-06 2015-11-06
US62/251,903 2015-11-06
PCT/US2015/061194 WO2016081523A1 (en) 2014-11-17 2015-11-17 Method for treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021008382A Division JP2021073241A (ja) 2014-11-17 2021-01-22 癌を処置する方法

Publications (3)

Publication Number Publication Date
JP2017537899A JP2017537899A (ja) 2017-12-21
JP2017537899A5 true JP2017537899A5 (enExample) 2018-12-27
JP6829684B2 JP6829684B2 (ja) 2021-02-10

Family

ID=56014476

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017526088A Active JP6829684B2 (ja) 2014-11-17 2015-11-17 癌を処置する方法
JP2021008382A Pending JP2021073241A (ja) 2014-11-17 2021-01-22 癌を処置する方法
JP2023027585A Active JP7485810B2 (ja) 2014-11-17 2023-02-24 癌を処置する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021008382A Pending JP2021073241A (ja) 2014-11-17 2021-01-22 癌を処置する方法
JP2023027585A Active JP7485810B2 (ja) 2014-11-17 2023-02-24 癌を処置する方法

Country Status (20)

Country Link
US (3) US10786511B2 (enExample)
EP (2) EP3220916B1 (enExample)
JP (3) JP6829684B2 (enExample)
KR (2) KR102644844B1 (enExample)
CN (2) CN116650500B (enExample)
AU (4) AU2015350108B2 (enExample)
BR (1) BR112017010166A2 (enExample)
DK (1) DK3220916T3 (enExample)
EA (1) EA201791095A1 (enExample)
ES (1) ES2947819T3 (enExample)
FI (1) FI3220916T3 (enExample)
HU (1) HUE062159T2 (enExample)
IL (4) IL296080B2 (enExample)
LT (1) LT3220916T (enExample)
MX (2) MX383484B (enExample)
PL (1) PL3220916T3 (enExample)
PT (1) PT3220916T (enExample)
SG (1) SG11201703806XA (enExample)
SI (1) SI3220916T1 (enExample)
WO (1) WO2016081523A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3363B1 (ar) 2011-04-13 2019-03-13 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
KR102021642B1 (ko) 2012-10-15 2019-09-16 에피자임, 인코포레이티드 암을 치료하는 방법
EP3076977B1 (en) 2013-12-06 2021-03-03 Epizyme, Inc. Combination therapy for treating cancer
BR112016029492A2 (pt) 2014-06-17 2017-10-17 Eisai R&D Man Co Ltd método para tratamento de linfoma não hodgkin
SG11201703806XA (en) * 2014-11-17 2017-06-29 Epizyme Inc Method for treating cancer
EA201792304A1 (ru) 2015-04-20 2018-03-30 Эпизайм, Инк. Комбинированная терапия для лечения рака
AU2016275051A1 (en) 2015-06-10 2017-12-07 Epizyme, Inc. EZH2 inhibitors for treating lymphoma
CN108025191A (zh) 2015-08-24 2018-05-11 Epizyme股份有限公司 治疗癌症的方法
WO2017132518A1 (en) 2016-01-29 2017-08-03 Epizyme, Inc. Combination therapy for treating cancer
US11786533B2 (en) 2016-06-01 2023-10-17 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
US11147819B2 (en) 2016-06-17 2021-10-19 Epizyme, Inc. EZH2 inhibitors for treating cancer
AU2018210099A1 (en) 2017-01-19 2019-08-15 Daiichi Sankyo Company, Limited Pharmaceutical composition used for treatment of HTLV-1-associated myelopathy
US11642346B2 (en) 2017-03-31 2023-05-09 Epizyme, Inc. Combination therapy for treating cancer
WO2018223030A1 (en) 2017-06-02 2018-12-06 Epizyme, Inc. Use of ezh2 inhibitors for treating cancer
CA3074720A1 (en) 2017-09-05 2019-03-14 Epizyme, Inc. Combination therapy for treating cancer
CA3162315A1 (en) * 2019-12-20 2021-06-24 Marinus Jacobus Verwijs Crystalline hydrobromide salt of a ezh2 inhibitor, its preparation and pharmaceutical composition useful for the treatment of cancer
JP7628876B2 (ja) 2021-04-23 2025-02-12 日立Astemo株式会社 情報処理装置、情報処理方法、プログラムおよび記憶媒体
US20250146080A1 (en) * 2022-02-17 2025-05-08 Memorial Sloan-Kettering Cancer Center Methods for overcoming tazemetostat-resistance in cancer patients
WO2023209591A1 (en) 2022-04-27 2023-11-02 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9119052D0 (en) 1991-09-06 1991-10-23 Boots Co Plc Pharmaceutical compositions
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US20070026064A1 (en) * 2005-07-29 2007-02-01 Yoder Steven L Pharmaceutical dosage forms having watermark-type identification and authentication inditia
WO2008121476A1 (en) * 2007-03-28 2008-10-09 Tapestry Pharmaceuticals, Inc. Biologically active taxane analogs and methods of treatment by oral administration
US20100278921A1 (en) * 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
AU2011298987B2 (en) 2010-09-10 2017-09-28 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
EP2663283B1 (en) * 2011-01-14 2017-05-10 Bristol-Myers Squibb Company High drug load tablet formulation of brivanib alaninate
EP3323820B1 (en) 2011-02-28 2023-05-10 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
JO3363B1 (ar) 2011-04-13 2019-03-13 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
HUE042271T2 (hu) 2012-03-12 2019-06-28 Epizyme Inc Emberi EZH2 inhibitorai és azok alkalmazási eljárásai
KR102117982B1 (ko) * 2012-04-13 2020-06-03 에피자임, 인코포레이티드 암 치료용 병용 요법
DK3628670T3 (da) * 2012-04-13 2022-12-05 Epizyme Inc Saltform til ezh2-hæmning
KR102021642B1 (ko) 2012-10-15 2019-09-16 에피자임, 인코포레이티드 암을 치료하는 방법
CN105102432B (zh) 2012-10-15 2019-01-04 Epizyme股份有限公司 经取代的苯化合物
EP2934531A4 (en) * 2012-12-19 2016-06-15 Glaxosmithkline Llc COMBINATION
AU2013361079B2 (en) 2012-12-21 2018-07-26 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
CA2894216A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. 1,4-pyridone compounds
US9776996B2 (en) 2013-03-15 2017-10-03 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
AU2014254392B2 (en) 2013-03-15 2018-05-24 Epizyme, Inc. Substituted benzene compounds
US10150764B2 (en) 2013-07-19 2018-12-11 Epizyme, Inc. Substituted benzene compounds
EP3057962B1 (en) 2013-10-16 2023-10-18 Epizyme, Inc. Hydrochloride salt form for ezh2 inhibition
AU2014337121A1 (en) 2013-10-18 2016-04-14 Epizyme, Inc. Method of treating cancer
EP3076977B1 (en) 2013-12-06 2021-03-03 Epizyme, Inc. Combination therapy for treating cancer
BR112016029492A2 (pt) * 2014-06-17 2017-10-17 Eisai R&D Man Co Ltd método para tratamento de linfoma não hodgkin
EP3160940A4 (en) 2014-06-25 2018-05-02 Epizyme, Inc. Substituted benzene and 6,5-fused bicyclic heteroaryl compounds
MX383635B (es) 2014-10-16 2025-03-14 Epizyme Inc Método para tratar el cáncer.
SG11201703806XA (en) 2014-11-17 2017-06-29 Epizyme Inc Method for treating cancer
AU2016275051A1 (en) * 2015-06-10 2017-12-07 Epizyme, Inc. EZH2 inhibitors for treating lymphoma
US11147819B2 (en) * 2016-06-17 2021-10-19 Epizyme, Inc. EZH2 inhibitors for treating cancer

Similar Documents

Publication Publication Date Title
ES2957912T3 (es) Composiciones farmacéuticas que comprenden nilotinib
KR102338802B1 (ko) 암을 치료하기 위한 방법
JP2023036772A (ja) ブルトンチロシンキナーゼの阻害剤を含む剤形組成物
US11065240B2 (en) Drug combinations to treat multiple myeloma
KR102490547B1 (ko) 퀴놀린 유도체로 갑상선암을 치료하기 위한 방법과 용도 및 갑상선암을 치료하기 위한 약학적 조성물
US12350246B2 (en) Eflornithine and sulindac, fixed dose combination formulation
WO2017075576A1 (en) Eflornithine and sulindac, fixed dose combination formulation
JP2021530554A5 (enExample)
JP2013536243A5 (enExample)
RU2712187C2 (ru) Фармацевтические композиции и их применение
ES2792574T3 (es) Formulación de Ceritinib
JP2015534985A5 (enExample)
KR20200121302A (ko) 간세포성 암종의 치료를 위한 조합 요법
JP7370126B2 (ja) エルロチニブを有効成分とする医薬錠剤
WO2011081118A1 (ja) 経口投与用医薬組成物
KR102330953B1 (ko) 소듐-1-[6-(모르폴린-4-일)피리미딘-4-일]-4-(1h-1,2,3-트리아졸-1-일)-1h-피라졸-5-올레이트를 함유하는 제약 투여 형태
KR102964530B1 (ko) 암을 치료하기 위한 방법
JP2018020968A (ja) ゲフィチニブを有効成分とする医薬組成物
JPWO2020246526A1 (ja) キサンチンオキシダーゼ阻害剤含有腸溶性製剤
EA048689B1 (ru) Твердый фармацевтический состав для лечения рака
HK1225281B (zh) 包含1-[6-(吗啉-4-基)嘧啶-4-基]-4-(1h-1，2，3-三唑-1-基)-1h-吡唑-5-醇钠的药物剂型
WO2015063669A1 (en) Pharmaceutical compositions comprising combination of roflumilast and acebrophylline or pharmaceutically acceptable salts thereof